PF-08057418

PF-08057418 is an investigational small molecule inhibitor of diacylglycerol O-acyltransferase 2 (DGAT2), currently being developed by Pfizer. DGAT2 is a key enzyme that catalyzes the final step in the synthesis of triglycerides. By inhibiting this enzyme, PF-08057418 aims to reduce hepatic triglyceride levels, which is a primary therapeutic strategy for treating metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH). The drug is currently in early-stage clinical development, with Phase 1 trials evaluating its safety, tolerability, and pharmacokinetics in healthy adult participants using both oral solution and tablet formulations.